trending Market Intelligence /marketintelligence/en/news-insights/trending/Y-GHm6tWeBEcEjhuN7snrg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Ideaya Biosciences closes $57.5M IPO on Nasdaq


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Ideaya Biosciences closes $57.5M IPO on Nasdaq

Ideaya Biosciences Inc. closed its $57.5 million IPO on the Nasdaq Global Market.

The South San Francisco, Calif.-based biotechnology company sold 5,750,000 common shares at $10 apiece, including full exercise by the underwriters of the option to purchase up to an additional 750,000 common shares.

The drugmaker previously said it intends to use the proceeds to develop eye cancer treatment IDE196, as well as other cancer therapy candidates.

Ideaya's shares started trading on the Nasdaq Global Market on May 23 under the symbol IDYA.

J.P. Morgan, Citigroup and Jefferies were the joint book-running managers for the IPO.